Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA).
Christopher Ryan HenryMilan ShahMark R BarakatPouya DayaniRobert C WangRahul N KhuranaLana RifkinSteven YehColette HallThomas A CiullaPublished in: The British journal of ophthalmology (2021)
Suprachoroidally administered CLS-TA was safe and well tolerated over the 24-week, open-label study in NIU subjects with and without MO.